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Abstract
Background: Industry-sponsored clinical trials, in the past performed almost exclusively in more developed
countries, now often recruit participants globally. However, recruitment from outside high-income countries may
not represent the ultimate target population for the intervention. Clinical trial registries provide an opportunity to
quantify and examine the type of clinical research performed in various geographic regions. We sought to
characterize industry-sponsored randomized controlled trials conducted in high-income countries and to compare
these trials to those performed outside high-income countries.
Methods: Clinical trial data on all industry-funded randomized controlled trials conducted between 2006 and 2014
were obtained from the registry ClinicalTrials.gov. Trials were classified according to their study sites as conducted
in high or non-high income countries, and data on trial characteristics were collected.
Results: Of 22,511 relevant trials, a total of 6,085 (27.0 %) trials included study sites outside a high-income country,
and 2,045 (9.1 %) were conducted exclusively outside high-income countries. Of country groups, Central Europe
had the greatest number of trials (3,127), followed by Eastern Europe (2,075). The percentage of trials with study
sites outside high-income countries remained relatively constant over the study period. Studies with sites outside
high-income countries tended to recruit more participants (median enrolled participants 265 vs. 71, P <0.001), to be
longer (median study duration 20 vs. 13 months, P <0.05), and to study more advanced phase interventions
(Phase 3 or 4 trial 58 % vs. 33 %, P <0.001).
Conclusions: More than a quarter of industry-sponsored trials include participants from outside high-income
countries and this rate remained stable over the 7-year study period. Trials conducted outside high-income
countries tend to be larger, have a longer duration, and study later phase interventions compared to studies
performed exclusively in high-income countries.
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Background
Industry-sponsored clinical research has traditionally
been performed in high-income countries, given the
established research infrastructure and the geographic
location of major pharmaceutical companies. Over
recent decades, however, globalization has led to the
extension of industry-sponsored clinical research out-
side higher income regions [1–3], with approximately
one-third of large company-sponsored phase III trials
being conducted exclusively outside the United States
of America. Indeed, the total number of countries
contributing results in major clinical trial publica-
tions between 1995 and 2005 has doubled [4, 5].
A number of factors contribute to the trend towards
more international study sites. First, the global burden
of disease is predominantly centred outside higher in-
come regions, potentially accelerating trial recruitment
for the large sample sizes required [6–8]. Secondly, in-
creasingly complex regulatory environments in higher-
income regions may slow down trial initiation and
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performance [9]. Thirdly, trials conducted in certain
non-higher income countries, such as Russia, Argentina
or China, may cost half the price of trials performed in
the United States or Western Europe [10]. Finally, recog-
nition of the growing market share of less-developed re-
gions may provide added incentive to have drugs tested
and approved in these countries [11].
This shift is not without controversies. Due to varying
regulatory and legal environments, clinical trials per-
formed outside high-income countries are presumed to
be different in design and conduct [12, 13]. Clinical trial
results from outside high-income countries may not be
applicable to high-income countries due to differences
in treatment effect sizes, rates of publication biases, and
genetically different populations [1, 3, 12–18]. Addition-
ally, ethical concerns about trial conduct outside higher
income regions persist, including access to study in-
terventions after trials are concluded and research
misconduct [2, 5, 18].
Our aim was to describe current patterns regarding
the globalization of industry-sponsored clinical trials,
including the number of trials performed in different
geographic regions and the collaboration between these
regions. Our secondary aim was to characterize and




We performed a cross-sectional analysis of industry-
sponsored clinical trials registered in ClinicalTrials.gov.
This registry is a USA-based registry of clinical trials
that represents as many as 86 % of all trial registrations
[19]. It has been used to assess various aspects of
clinical research activity, including correlation with
disease burden, quality of clinical trials, and publica-
tion bias [20–22].
We identified all interventional trials with any funding
by industry with a start date between January 1, 2006
and February 19, 2014 (date of data download). Trials
studying a drug, device, biologic or dietary supplement,
and employing a randomized design were selected. Trials
without information on study location were excluded.
Ethical approval was not obtained, given the nature of
the study.
Data extraction
We extracted data for each trial on study start and com-
pletion dates, allocation strategy, masking, trial phase,
estimated enrolment number, major condition group,
participant age eligibility, funding source, study site loca-
tions and number of sites, completion status, and post-
ing of trial results. Information was collected on both
lead and secondary funding sources. Condition groups
were defined by the investigators for easily-defined con-
ditions with a large disease burden (Additional file 1).
Country classification
Countries were geographically classified according to the
categorization used in the Global Burden of Disease pro-
ject which classifies countries into 21 regions and these
regions into five major geographic groups (Fig. 1), avail-
able at http://ghdx.healthdata.org/country_profiles [23].
The major groups are Asia, Africa/Middle East, Europe
(non-Western), Americas, and High-income regions.
The regions classified as High-income are High-income
Asia Pacific, High-income North America, Australasia,
and Western Europe. We considered all countries falling
into one of these regions as high-income and all others
as non-high income.
This categorization allows for both geographic and
economic stratification, and is consistent with both
World Bank income-based definitions and established
clinical research infrastructure [13]. Countries were clas-
sified based on all the study sites listed in the registry
record. Trials with study sites in both income regions
were included in both.
Data analysis
Descriptive analyses were performed quantifying study
sites and trials and describing trial characteristics by re-
gion and major geographic group. Differences were com-
pared with χ2 and Mann–Whitney tests. Time series
analysis was performed with regression analysis. All stat-
istical analyses were performed with R (R: A Language
and Environment for Statistical Computing, version
3.1.1, Vienna Austria, 2014).
Results
There were 41,149 industry-funded, interventional trials
registered in ClinicalTrials.gov with start dates during
the study period. Of these, 22,511 were randomized and
information on study site location was included (Fig. 2).
A total of 2,045 (9.1 %) trials were conducted exclu-
sively in non-high-income countries and an additional
4,040 (17.9 %) included sites in both high- and non-
high-income countries (Table 1). The remainder of the
trials (73.0 %) were conducted exclusively in high-
income countries. Central Europe represented the less-
developed country region with the greatest number of
trials (N = 3127), followed by Eastern Europe (N = 2075)
and East Asia (N = 1742). When adjusted for population,
the country regions Central Europe, Southern Latin
America, and Southern Sub-Saharan Africa represented
the non-high-income regions with the greatest number
of trials (Table 1).
In terms of number of study sites, 23 % of all sites
were outside high-income countries. Trials conducted in
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Asia were the most likely to recruit exclusively outside
high-income countries (42.1 % of all trials with sites in
Asia) followed by the Americas (19.8 %).
Among the major geographic groups, Europe (non-
Western) had the highest rate of collaboration with the
high-income regions, with 91.3 % of trials conducted
having a high-income collaborating site, while trials with
sites in Asia had the lowest rate, with 57.9 % of trials
including a site in a high-income region. Among the
country regions, trials in Eastern sub-Saharan Africa,
East Asia, and Western sub-Saharan Africa were most
frequently conducted without collaborating sites in high-
income countries, while trials with study sites in Southern
Latin America, Oceania, and Andean Latin America had
the highest rates of collaboration with high-income coun-
tries (Fig. 3).
Figure 4 shows trends in the rate of trials with study
sites in the different geographic groups. The percentage
of trials with study sites in non-high-income regions
remained relatively constant over the study period
(Fig. 4a). Similarly, there were no trends in the percent-
age of trials performed exclusively within non-high-
income major geographic groups, although there was
some fluctuation in rates, especially for the Americas
and Asia (Fig. 4b). At the same time, decreases were ob-
served in the percentage of trials with any study site in
the Americas (P = 0.02) and in the Middle East/Africa
(P = 0.01; Fig. 4c). Europe (non-Western) remained the
non-high-income geographic group with the highest par-
ticipation in trials, followed by Asia and the Americas.
Trials performed in high- and non-high-income coun-
tries (Table 2) differed. For trials performed exclusively
within one of the five major geographic groups, those
performed outside high-income regions enrolled signifi-
cantly more participants than trials in the high-income
group. Trials performed exclusively in the Americas,
Middle East/Africa, or Asia were less likely to use
double-blinding compared to those performed in high-
income regions. A greater proportion of trials in the
Fig. 1 Global map of regions and major geographic groups
Fig. 2 Flowchart of included trials
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Table 1 Clinical trial sites among industry-sponsored trials registered in ClinicalTrials.gov
Major geographic groups and country regions Total number of trials a
(N = 22,511)
Trials conducted exclusively outside





America 2,245 445 (19.8) 22,296 36.7
Andean Latin America 444 22 (5.0) 1,507 78.2
Caribbean 138 28 (20.3) 614 35.4
Central Latin America 1,321 143 (10.8) 6,902 53.7
Southern Latin America 1,139 69 (6.1) 7,239 182.3
Tropical Latin America 1,067 231 (21.6) 6,034 51.5
Middle East/Africa 1,447 203 (14.1) 8,294 10.1
Eastern Sub-Saharan Africa 55 43 (78.2) 197 1.4
North Africa and Middle East 727 85 (11.7) 2,875 14.6
Central sub-Saharan Africa 57 11 (19.3) 41 5.7
Southern sub-Saharan Africa 911 60 (6.4) 4,903 121.8
Western sub-Saharan Africa 97 39 (40.2) 278 2.6
Asia 2,845 1198 (42.1) 23,448 7.6
Central Asia 107 19 (17.8) 291 12.4
East Asia 1,742 728 (41.8) 11,502 12.6
Oceania 39 2 (5.1) 16 40.6
South Asia 1,157 324 (20.0) 7,234 7.1
Southeast Asia 867 161 (18.6) 4,405 13.7
Europe (non-Western) 3,536 308 (8.7) 58,960 109.0
Eastern Europe 2,075 159 (7.7) 20,685 99.6
Central Europe 3,127 200 (6.4) 38,275 269.0
More-developed 20,466 – 378,331 207.5
Australasia 1,775 – 9,718 643.1
Western Europe 8,591 – 123,019 202.5
High-income Asia Pacific 2,859 – 23,441 155.9
High-income North America 12,992 – 222,153 369.8
a Trials with study sites in more than one country region were included separately in each region
b Population data from World Bank, 2013. Available at data.worldbank.org
Fig. 3 Percentage of trials performed in non-high income regions with a collaborating site in a high-income country
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Americas, Asia, and Europe (non-Western) had industry
as a lead sponsor, and all four non-high-income geo-
graphic groups were more likely to study late phase in-
terventions than the high-income group.
Additionally, trials performed with at least one study
site in a non-high-income country had a larger median
number of sites (25 vs. 1, P <0.001), enrolled a greater
median number of participants (265 vs. 71, P <0.001),
and were more likely to have industry as the lead
funder (94.6 % vs. 80.8 %, P <0.001) compared to tri-
als with sites exclusively in high-income countries
(Table 3). Trials with sites in non-high-income coun-
tries were also more likely to be phase 3 or 4 trials




Fig. 4 Temporal trends in trial performance by geographic group. a Percentage of trials performed in high and non-high-income geographic
groups from 2006 to 2013; (b) Percentage of trials performed exclusively outside high-income major geographic group; (c) Percentage of trials
performed with at least one study site outside the high-income geographic group. There were significant decreases in trials performed with sites
in Middle East/Africa or the Americas (P = 0.01 and 0.02, respectively)
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duration (20.3 months vs. 13.2 months, P <0.05) than tri-
als performed in more-developed countries. The propor-
tion of trials with sites outside high-income regions was
highest for trials studying diabetes (54.4 % of trials), with
healthy volunteer studies having just 9.9 % of trials
conducted with a site outside a high-income region
(Table S1, Additional file 1). Of the 1,236 trials performed
in children, 537 (43.4 %) had a site outside a high-income
country with similar trends existing regarding rate of
double-blinding, advanced phase, and study size when
compared with all other trials (Additional file 1:
Table S2).
Discussion
We found that more than a quarter of trials registered in
ClinicalTrials.gov are recruiting participants in non-
high-income countries, with the majority of these trials
enrolling in both high- and non-high-income countries.
Table 2 Characteristics of industry-sponsored clinical trials performed exclusively within one major geographic group a
Study characteristic Major geographic group
Americas N = 406 Middle East/Africa
N = 163




Median study sites, N (IQR) 1 c 1 c 1 c 2 c 1
(1–2) (1–3) (1–4) (1–9) (1–9)
Median subjects enrolled, N (IQR) 100 c 183 c 142 c 120 c 71
(48–200) (90–400) (50–300) (47–259) (33–188)
Double-blinded, N (%) 191 c 73 c 502 c 168 9938
(46.9) (44.7) (44.1) (65.6) (61.1)
Industry as lead funder, N (%) 345 c 115 c 998 c 236 c 13 133
(84.8) (70.5) (87.7) (92.2) (80.8)
Phase 3 or 4, N (%) 250 c 73 c 589 c 104 c 5345
(61.6) (44.7) (51.7) (40.6) (32.9)
Paediatric b N (%) 42 c 51 c 120 c 28 c 699
(10.3) (31.3) (10.5) (10.9) (4.2)
a 18,209 (80.9 %) of all trials were conducted exclusively in one region and are included in the table
b Defined as listed maximum age <19, or if listed maximum age above 19, median age <19. If no maximum age listed, trial assumed to be adult
c P <0.05 by χ2 or Mann–Whitney testing when compared with high-income regions
Table 3 Characteristics of industry-sponsored clinical trials by study site income level
Trial characteristic All trials N = 22,511 Trials with study sites
outside high-income
countries, N = 6,085
Trials with study sites
exclusively in high-income
countries, N = 16,426
P value c
Median study sites, N (IQR) 3 (1–20) 25 (4–71) 1 (1–9) <0.001
Median participants enrolled, N (IQR) 100 (40–283) 265 (104–554) 71 (33–186) <0.001
Double-blinded, N (%) 13,883 (61.7) 3,945 (64.8) 9,938 (61.1) <0.001
Industry as lead funder, N (%) 18,891 (83.9) 5,758 (94.6) 13,133 (80.8) <0.001
Sponsored by one of the 10 largest pharmaceutical
companies a N (%)
5,522 (24.5) 2,182 (35.9) 3,340 (20.3) <0.001
Phase 3 or 4, N (%) 8,877 (39.4) 3,532 (58.0) 5,345 (32.9) <0.001
Paediatric b N (%) 1,236 (5.5) 537 (8.8) 699 (4.2) <0.001
Median trial length, months d 15.2 (7.1–27.4) 20.3 (12.2–34.5) 13.2 (6.0–25.3) <0.05
Completed, N (%) e 11,703/16,296 (71.8) 3,011/4,392 (68.5) 8,692/11,904 (73.0) <0.001
With results posted on ClinicalTrials.gov, N (%) f 3,142/11,703 (26.8) 1,001/3,011 (33.2) 2,141/8,692 (24.6) <0.001
a Pfizer, Novartis, Sanofi, Merck, Roche, GlaxoSmithKline, Abbott, AstraZeneca, Amgen, Eli Lilly as defined by total revenues at Forbes.com
b Defined as listed maximum age <19, or if listed maximum age above 19, median age < 19. If no maximum age listed, trial assumed to be adult. See Additional
file 1 for further details (Table S2)
c χ2 or Mann–Whitney for medians
d Available in 21 223 trials
e Among trials started before January 1, 2012
f Among trials labelled as complete and started before January 1, 2012
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Of the non-high-income geographic groups, Europe
(non-Western) and Asia have the greatest proportion of
trials.
Trials performed in different regions of the world dif-
fer substantially; those conducted in non-high-income
countries recruit from a greater number of study sites
and study more advanced-phase interventions. Trials
with sites in non-high-income countries also tend to re-
cruit more subjects when compared to those conducted
exclusively in high-income countries, indicating that
subjects from non-high-income countries may contrib-
ute substantially to trial results. This is consistent with
the limited prior work examining potential differences in
trial characteristics conducted in high- and non-high-
income countries [24–26].
There are a number of factors underlying the ongoing
trend of recruiting participants from non-high-income
countries. The lower cost is likely a key driver, as
evidenced by the high number of sites and large trial
sizes among trials conducted in non-high-income re-
gions such as Europe (non-Western) and Asia [10]. In
addition, the ease of recruitment of treatment-naïve
patients with chronic disease makes non-high-income
countries appealing for subject recruitment [27].
Anthropological analyses of international research
have described three phases, where the first is a massive
influx of research infrastructure into a non-high-income
region, the second an increase in the regulatory environ-
ment with more stringent oversight, and the third, a
shift towards specific demands about the nature of the
proposed research by local researchers and patients [28].
It is uncertain where on this continuum research activity
currently lies among the regions examined, but the
relatively stable activity in the regions may indicate that
they may have entered the second or third phases with
greater local involvement. Prior studies documenting
substantial increases in trial activity in many of these
non-high-income regions up through 2005 would fur-
ther support this possibility [4, 5].
A number of factors should be considered when ex-
trapolating trial results from non-high-income clinical
settings to high-income countries. For one, ethical stan-
dards differ by region, despite the existence of inter-
national frameworks, leading to potential exploitation of
participants [1, 29]. Streamlining regulatory oversight
across regions would allow for the maintenance of trial
standards, negating the search for more lax regions in
which to perform studies. In addition, prior work sug-
gests that non-high-income countries have larger effect
sizes for interventional studies, raising concerns that the
populations in high-income countries may not experi-
ence the benefits predicted by premarket trials [13].
One postulated reason for this effect size difference
is the narrow targeting of treatment-naïve patients
with advanced phase interventions in non-high-income
countries.
One of the limitations of this study is that there is
no definitive classification for high- and non-high-
income countries and, while we used a widely ac-
cepted categorization scheme, some of the countries
may have been classified differently using other ap-
proaches. In addition, the accuracy of the data provided
in ClinicalTrials.gov relies on investigators and we were
not able to verify the information. There is also missing
data in the registry, although we encountered only a
small proportion of missing information for the variables
of interest. Finally, although ClincialTrials.gov is the lar-
gest and most comprehensive trial registry, it is possible
that some trials were not registered or were registered in
other, country-specific registries. However, this likely
represents a very small number of trials since all
pharmaceutical companies seeking Food and Drug
Administration approval of a drug (which is required
for marketing in the USA) must register their trials in the
ClinicalTrials.gov registry.
Conclusions
More than a quarter of all pharmaceutical company tri-
als recruit participants from non-high-income nations.
The percentage of trials in non-high-income countries
remained stable over the seven-year study period. There
are a number of differences in the design and conduct of
trials in high and non-high-income countries, including
trials in non-high-income countries enrolling more par-
ticipants and studying later phase interventions. The sci-
entific implications of participant recruitment from
these diverse geographic regions and of the differences
in trial characteristics in different regions warrant fur-
ther exploration.
Additional file
Additional file 1: Table S1. Subgroup analyses of major conditions.
Cardiovascular is defined as studies meeting search criteria for conditions
involving coronary artery disease, cardiac dysfunction, or known risk factors
for the above such as hypercholesterolemia and hypertension. Psychiatric
trials were defined as studies meeting search criteria for common psychiatric
disorders. Diabetes, asthma, and COPD were searched using their respective
terms. Table S2. Trials involving children, defined as listed maximum
age <19, or if listed maximum age above 19, median age <19. If no
maximum age listed, trial assumed to involve adults. Figure S1. Top
10 pharmaceutical companies and studies with sites outside high-income
regions, as defined by total revenues at Forbes.com.
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